Vaccine manufacturer news

Western Companies Moderna (UK). Moderna has opened a new mRNA vaccine manufacturing facility in Oxfordshire, UK, with the capacity to produce approximately 100 million doses annually under steady-state conditions, scalable to around 250 million doses in the event of a pandemic. The launch was announced alongside a £50 million life sciences fund to attract large-scale projects. https://www.gov.uk/government/news/millions-of-vaccines-to-be-made-in-oxfordshire-and-government-unveils-50-million-fund-in-double-boost-for-life-sciences Moderna (Canada). Canada marked a milestone in September 2025, as Moderna’s Quebec facility produced its first domestically manufactured mRNA COVID-19 vaccine doses, strengthening national supply security and pandemic preparedness. https://www.canada.ca/en/innovation-science-economic-development/news/2025/09/government-of-canada-announces-major-milestone-in-the-canadian-biomanufacturing-sector.html Valneva (chikungunya). Although the U.S. FDA suspended the license of Valneva’s chikungunya vaccine IXCHIQ® in August 2025 following safety concerns, the company reported a 95% seroresponse four years after a single dose, demonstrating durable long-term antibody levels. https://valneva.com/press-release/valneva-reports-95-seroresponse-four-years-after-single-shot-of-chikungunya-vaccine-ixchiq/ Asia India. The Serum Institute of India announced a partnership with Vidal Health to expand access to HPV vaccines nationwide. The collaboration aims to improve vaccination coverage against cervical cancer by strengthening outreach...